In an effort to develop potent and secure antiproliferative lead compounds, five quinolinequinones (AQQ1‐5) described previously have been selected and submitted to the National Cancer Institute (NCI) of Bethesda. Four of five quinolinequinones (AQQ2‐5) were selected for five‐dose screening and they displayed promising antiproliferative effects against several cancer types. All AQQs showed a super anticancer profile with low micromolar GI50 and TGI values against most cell lines. AQQ2‐5 reduced the proliferation of all some cell lines at a single dose and five additional doses. We investigated the in vitro cytotoxic activities of the most promising compounds, AQQ2 and AQQ3. Concomitantly, IC50 values of AQQ2 against MCF7 and T‐47D cell lines of breast cancer, DU‐145 cell line of prostate cancer, HCT‐116 cell line of colon cancer, and HaCaT human keratinocytes were determined. AQQ2 exhibited anticancer activity through the induction of apoptosis and caused alterations in the cell cycle. In silico pharmacokinetic studies of all analogs have been carried out against ATR, CHK1, WEE1, CDK1, and CDK2. In addition to this, in vitro ADME and in vivo pharmacokinetic profiling for the most effective AAQ (AAQ2).